Frier Levitt attorneys recently reversed roughly ninety-six percent (96%) of the audit findings issued by a major PBM against a Georgia-based pharmacy. With the help of Frier Levitt’s guidance, the Pharmacy compiled supporting documentation that... Read More
The pharmacy benefits landscape is changing for large employer groups and affecting all parties in the drug supply chain. Recent federal actions, such as the Federal Trade Commission’s investigation into Pharmacy Benefit Managers (“PBMs”)... Read More
On November 15, 2023, Frier Levitt attorneys Dae Lee, Harini Bupathi, and Adam Farkas hosted a comprehensive webinar delving into the most common issues pharmacies faced when audited by Pharmacy Benefit Managers (“PBMs”) in 2023, and what... Read More
Frier Levitt successfully reversed one hundred percent (100%) of the audit findings issued by a major PBM against a Michigan-based pharmacy. During the audit, the PBM asserted a host of allegations against the pharmacy. Under Frier Levitt’s... Read More
Throughout 2023, PBMs have intensified their scrutiny of pharmacies and their network participation. The outcomes of these PBM audits and investigations have led to significant monetary penalties, disruptions in network operations, and further... Read More
As discussed in our recent article, the end of the calendar year brings with it Pharmacy Benefit Manager (“PBM”) end-of-year “housekeeping,” where PBMs intensely review credentialing materials and PBM audit histories to determine which... Read More
Auto-refill policies are a convenience-driven approach to pharmacy services, designed to ensure that patients with chronic conditions receive their medications in a timely manner. Through pharmacy software programs, pharmacies can automatically... Read More
Recently, Frier Levitt assisted a Texas based pharmacy client in challenging a major Pharmacy Benefit Manager’s (“PBM”) audit findings. After receiving the initial audit findings, the Pharmacy compiled the necessary documentation to address... Read More
The rising cost of prescription drugs impacts all members of the pharmacy supply chain. For patients, it likely means higher copay or co-insurance responsibilities under their prescription benefit plan. Excessive patient pay amounts deter... Read More
Congress has taken yet another major step towards controlling prescription drug prices and promoting affordability for Medicare Beneficiaries. On June 14, 2023, Senators Wyden, Crapo, Menendez, Blackburn, Tester and Marshall introduced bipartisan... Read More
